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article under the CC BY-NC-ND licenseAbstract Ureteral stents are commonly used following urological procedures to maintain ure-
teral patency. However, alongside the benefits of the device, indwelling stents frequently
cause significant patient discomfort (pain, urgency, frequency) and can become encrusted
and infected. The importance of these sequelae is that they are not only bothersome to the
patient but can lead to significant morbidity, urinary retention, ureteral damage, recurrent in-
fections, pyelonephritis and sepsis. When these problems occur, stent removal or replacement
alongside antibiotic, analgesic and/or other symptom-modifying therapies are essential to suc-
cessfully treat the patient. In an attempt to prevent such morbidity, numerous approaches
have been investigated over the past several decades to modify the stent itself, thereby
affecting changes locally within the urinary tract without significant systemic therapy. These
strategies include changes to device design, polymeric composition, drug-elution and surface
coatings. Of these, drug-elution and surface coatings are the most studied and display the most
promise for advancing ureteral stent use and efficacy. This article reviews these two strategies
in detail to determine their clinical potential and guide future research in the area.
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Drug-eluting stents and stent coatings 1951. Introduction
Ureteral stents are widely used in urology to maintain
urinary flow from the kidney to the bladder in the presence
of kidney stones and other obstructing lesions including
strictures and extrinsic causes. While the vast majority of
these devices are placed for a relatively short amount of
time (1e2 weeks), a portion of patients will require more
chronic (weeks to years) of ureteral stenting. For those
requiring short-term stenting, pain and discomfort caused
by the device are the most common symptoms, especially
during activity and urination. This is typically managed
using oral nonsteroidal anti-inflammatory drugs (NSAIDs) or
other analgesic medications but can still result in patients
presenting with moderate to severe urinary symptoms
during the indwelling period. A small portion of patients
may also develop stent-related infection and/or encrus-
tation, but since the devices are only in for a short period
of time, encrustation will typically be minor and infection
can often be adequately dealt with using broad-spectrum
antibiotics until device removal. Chronically-stented pa-
tients are more difficult to manage as they face all of the
above sequelae on a continuous basis and often require
new stents to be inserted immediately following the
removal of any infected or encrusted device. This short
turnaround time between stents enhances direct transfer
of organisms from an infected device or urinary environ-
ment to the new one and once organisms securely adhere
to the new device and form a biofilm, they are virtually
impossible to eradicate. Even the use of high-dose anti-
microbial agents alongside device replacement does not
always prevent infection, as the same organism has often
been cultured from the replacement stent even months
later.
Question 1: Is there any other way to avoid urinary
catheter-associated infection and other discomfort?
To date, no ureteral stent adequately addresses the
issues of pain, discomfort, infection and encrustation
associated with their use. However, numerous approaches
have been employed in an attempt to do so, primarily the
development of novel surface coatings and drug-elution
strategies. This review focuses on these two areas of
research to determine their potential in preventing
stent-associated infections, encrustation and patient
symptoms.
2. Stent coatings
Question 2: Surface coatings for ureteral stents typically
target the prevention of infection and encrustation by
inhibiting bacterial attachment and survival on the device,
as well as resisting urinary crystal formation and adher-
ence. Numerous strategies have been developed and
tested, largely based upon the application of anti-adhesive
(modifying surface charge, hydrophobicity and roughness)
and antimicrobial (silver, antibiotics, detergents, others)
compounds. What are their characteristics and what situ-
ations are they best suited for?2.1. Heparin
Heparin is a highly-sulfated glycosaminoglycan widely
used in medicine for a number of clinical indications,
predominantly anticoagulation. Due to its relative safety,
high negative charge and existing use as an anti-adhesive
coating on blood-related tubing and devices, the mole-
cule has been applied to urinary stents and tested for its
ability to reduce biofilm formation and encrustation
(Endo-Sof, Radiance, Cook Urological). In addition to
the heparin coating, this stent possesses thermosensitive
properties that allow more rigidity during placement
followed by a softening once exposed to body tempera-
ture, promoting increased patient comfort. An initial
study involving two patients with stents indwelling for 10
and 12 months showed no encrustation as well as no
changes in the heparin layer, suggesting that it might be
a useful tool for long-term urinary drainage [1]. However,
a subsequent in vitro study by Lange et al. [2] failed to
show any benefit for the heparin-coated device over
controls in resisting bacterial adherence. Ultimately,
further studies need to be conducted to determine
whether stents with a heparin coating have true poten-
tial as long-term devices able to resist both encrustation
and biofilm formation in vivo.
2.2. Diamond-like carbon coatings
Although the development and use of diamond-like carbon
coatings (DLCs) for reduced friction and wear have been
studied for decades, the first description of their applica-
tion on urological deviceswas in 2004 by Dr. Norbert Laube’s
research group [3] at the University of Bonn, Germany. They
applied a plasma-deposited, diamond-like amorphous car-
bon material to segments of both urethral catheters and
ureteral stents and demonstrated preliminary efficacy in
reducing encrustation and ease of insertion. Based upon its
overall nanocrystalline structure, outer monomolecular
layer of non-polar hydrogen atoms and thin filmapplication,
the coating is chemically inert, biocompatible, superlubri-
cious and extremely durable. That initial workwas followed
by both in vitro and in vivo studies published in 2007 that
demonstrated great promise in reducing patient symptoms,
infections and encrustation [4,5]. The latter study involved
10 chronically-stented patients suffering from numerous
underlying disorders and requiring frequent stent changes
due largely to heavyencrustation. Several different types of
uncoated, polyurethane Double J stents were coated and 26
devices placed for a total of almost 2500 days across this
population. Overall, the results showed reduced encrusta-
tion, biofilm formation, patient symptoms and complica-
tions, and also increased physician ease in device handling,
placement and removal. Unfortunately, no further studies
investigating this coating strategy on urological devices
have been published since. Future studies should target
short-term patients to investigate whether significant
decreases in infection rates can be achieved in this
population.
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Another coating displaying superlubricious properties is
polytetrafluoroethylene (PTFE), also known as Teflon.
First discovered in 1938 by Dr. Roy Plunkett while trying to
develop novel chlorofluorocarbon refrigerants, the strongly
hydrophobic compound has since been used as a non-stick
surface and lubricant in a plethora of applications, from
non-stick frying pans to lubricants, seals and insulation in
rocket tanks and telescopes used by NASA. Indeed, PTFE’s
coefficient of friction (0.05e0.1) is one of the lowest of any
known substance, behind only aluminum-magnesium-boron
polymers (0.02) and rivaling those of diamond-like carbon
compounds (0.05e0.2) described above. Furthermore, its
resistance to van der Waals forces, commonly used by
bacteria for initial surface attachment, offer promise in
resisting bacterial colonization and biofilm development.
While numerous in vitro studies conducted over the past 2
decades have shown Teflon-coated surfaces to reduce
protein adherence and bacterial attachment versus con-
trols, other studies have found that some proteins and
bacteria, largely those with strong hydrophobic properties,
are not affected [6,7]. Chung et al. [8] tested PTFE-covered
metallic stents and found them to prevent hyperplasia in
comparison to non-covered devices in a canine ureter
model. The covered stents were also found to be patent
during both short and intermediate time frames. Ulti-
mately, further long-term studies are required to comment
on long-term patency in patients and additional work is
needed to specifically evaluate urinary pathogens for their
ability to colonize and cause infection on these coatings.
2.4. Hydrophilic coatings
Hydrophilic coatings have been well explored as stent
coating alternatives due of course to their hydrophilic
properties, which act as a deterrent to hydrophobic bac-
terial surfaces and encrusting deposits within the urine.
Polyethylene glycol (PEG) is a commonly used hydrophilic
coating due to its success as an antifouling agent, a result
of its high degree of mobility and steric hindrance in
chemical structure [9]. The structure of this polyether al-
lows it to couple numerous water molecules, reducing its
coefficient of friction and driving its fluid-like behavior.
Research into PEG as a coating has demonstrated resistance
to bacterial, protein and mammalian cell attachment [10],
suggesting that PEG may be capable of resisting condi-
tioning film development. Concerns regarding the use of
PEG arise in the inability to anchor enough molecules to
generate a dense coating and the prevention of its thermal,
oxidative, or hydrolytic degradation during the anchoring
process. To overcome these drawbacks researchers have
developed novel approaches for attaching PEG to surfaces
including the use of 3,4-dihydroxyphenylalanine (DOPA), a
peptide mimic based on the adhesive proteins used by
mussels for attachment in marine environments [11].
Through in vitro and in vivo studies DOPA conjugated PEG
has proven effective; demonstrating inhibition of both
conditioning film and biofilm development [12], along with
a significant reduction in uropathogenic Escherichia coli
adherence in a rabbit model of cystitis [13]. More recently,Liu and colleagues [14] demonstrated the suitability of PEG
as a coating agent in paclitaxel-eluting stents.
In 2007, John and colleagues [15] demonstrated that hy-
drophilic gel (hydrogel) coated stent segments did not reduce
bacterial adhesion compared to controls. However, when
stent segments were pre-dipped in antibiotic solutions prior
to incubation with E. coli or Enterococcus faecalis on agar
plates, there was significantly more growth inhibition in the
hydrogel-coated groups depending on the organism and
antibiotic used. For instance, the cefazolin/hydrogel coated
stents produced the largest zones of bacterial growth inhi-
bition but only displayed a short duration of activity; hydro-
gel/ciprofloxacin and hydrogel/gentamicin combinations
showed standard inhibition zones but were found to possess
longer durations of activity. Thus the coupling of hydrogel
coated and drug-eluting stents may prove advantageous.
2.5. Silver
Silver has been widely used as an antimicrobial agent for
centuries, from preventing food spoilage by ancient civili-
zations to preventing and treating wound infections, to its
current use in the eyes of newborn babies immediately
following delivery. One advantage of the compound is that
while it exhibits broad-spectrum antimicrobial activity like
several other heavy metals, it lacks the concomitant host
toxicity. While precise mechanisms for all of its antimi-
crobial activities are still lacking, silver is known to cause
bacterial membrane destabilization and to strongly bind
numerous bacterial enzymes, abolishing their activity [16].
Silver-coated urethral catheters have been in use for over
20 years but their true efficacy is still a matter of much
debate. Several meta-analyses comparing over 20 different
studies have made a case that silver alloy (but not silver
oxide) coated devices are effective in reducing overall
catheter-associated UTI rates by up to 45% [16,17]. How-
ever, a recent systematic review conducted by Beattie and
Taylor [18] indicated that although the collective evidence
favors the use of silver-alloy urinary catheters in reducing
catheter-associated UTI, it cannot make a definitive
conclusion owing to the poor quality of some studies as well
as their significant heterogeneity. Furthermore, Liu et al.
[14] indicated that silver alloy-coated catheters might in-
crease the risk of developing urethral strictures following
robotic-assisted laparoscopic radical prostatectomy
compared to uncoated controls. Collectively, the overall
lack of a definitive stance on the efficacy of silver in the
urinary tract, coupled with the slightly higher cost of Ag-
coated catheters, has resulted largely in indifferent and
inconsistent use of the devices as well as a lack of the ion’s
incorporation into current stent coating technologies.
Future work involving silver as a constituent of stent
coatings is definitely warranted, perhaps in combination
with other antifouling and/or antimicrobial strategies as an
additional line of defense.
2.6. Antimicrobial peptides
Antimicrobial peptides are small molecular weight proteins
with broad-spectrum antimicrobial activity against bacte-
ria, viruses and fungi. They are considered one of the most
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a wide variety of life forms ranging from insects to humans.
Antimicrobial peptides are very diverse in both their
structure and mechanism of action. RNAIII-inhibiting pep-
tide (RIP) is a heptapeptide that is highly effective in the
treatment of polymicrobial, as well as drug-resistant in-
fections. In Staphylococcus aureus, RIP has been demon-
strated to downregulate expression of genes involved in
biofilm formation and toxin production; while upregulating
genes involved in stress responses and inhibiting cell-to-cell
communication [19e21]. RIP-coated ureteral stent seg-
ments implanted in rat bladders have been shown to reduce
both adherence to the stent and survival of planktonic cells
by 99% compared to uncoated controls [20]. Moreover,
when the coated stent was combined with systemic
administration of teicoplanin, both adherent and plank-
tonic bacterial levels were reduced by almost 1 million
fold. The theory behind this synergistic effect lies in the
reduction of adhesion and biofilm formation by RIP, allow-
ing teicoplanin to exert bactericidal effects on any cells
present in the urinary tract. Additionally, a non-peptide
based analog with similar effects has been discovered by
researchers at Tufts University [22].
Tachyplesin III is another antimicrobial peptide that has
been thoroughly studied. Originally isolated from hemo-
lymph of Southeast Asian horseshoe crabs, Tachyplesin III
has 17 amino acids with two disulfide bridges and a cyclic b-
sheet structure [23]. The antimicrobial peptide exhibits
broad-spectrum activity against Gram-negative and posi-
tive bacteria, as well as fungi. In 2007, Cirioni et al. [20]
demonstrated Tachyplesin III’s powerful bactericidal role
against multi-drug resistant isolates of Pseudomonas aeru-
ginosa. In the same year, Minardi et al. [24] showed that
Tachyplesin III coated ureteral stents inhibited bacterial
growth by almost 1000 fold compared to uncoated stents
in vivo, highlighting the potential of this antimicrobial as a
stent coating.
Another alternative that has yet to be studied for uro-
logical applications is melamine, a synthetically derived
antimicrobial peptide, that incorporates the active regions
of protamine (from salmon sperm) and melittin (from bee
venom) [25]. Melamine is effective against both Gram-
positive and negative bacteria and has been documented
to retain activity when covalently attached to contact
lenses in vitro. Further, the peptide is not cytotoxic at
active concentrations and bacteria do not appear to readily
gain resistance. When tested in both guinea pig and rabbit
models, melamine contact lenses were found to prevent
bacterial growth [26]. As such, the use of melamine cova-
lently linked to ureteral stents may represent an antimi-
crobial peptide of interest to researchers active in stent
development.
3. Drug-eluting stents
As discussed earlier, the patient discomfort surrounding
stent placement is a significant factor in quality of life
considerations by urologists. A commonly used manage-
ment strategy for stent discomfort is through oral agents;
however this treatment method is associated with possibleside effects and minimal efficacy [27,28]. As such, re-
searchers have explored the use of local drug delivery as an
alternative. Research into local drug delivery methods has
assessed both drug-coated and drug-eluting devices. Drug-
eluting stents (DES) have been used widely in the treat-
ment of cardiovascular disease and significant progress has
been made in the past few years to evaluate the use of DES
in the urinary tract.
Question 3: Regarding the prevention of device-
associated urinary tract infections and reduction of pa-
tient discomfort, what viable drug-eluting stent options are
available and how efficacious are they?
3.1. Triclosan
Triclosan is a broad-spectrum antimicrobial with a long
(over 40 years) history of use in numerous medical and
hygienic products [29]. Dependent upon the concentration
used and organism targeted, triclosan can act either bac-
teriostatically or bacteriocidally. Its primary known
mechanism of action is the binding and subsequent inhi-
bition of the enoyl-acyl carrier protein reductase (Fab I),
an enzyme critical for bacterial fatty acid biosynthesis. At
higher (bactericidal) concentrations it is believed to also
act through additional targets including membrane desta-
bilization [30,31]. A plethora of work done in the oral
cavity and on the skin over the past several decades have
demonstrated a combination of strong antimicrobial and
anti-inflammatory effects at both body sites, suggesting
that it may exhibit similar properties in the urinary tract
and potentially help reduce bacterial UTIs and their asso-
ciated symptoms. Based upon this hypothesis, a ureteral
stent impregnated with triclosan was developed by Boston
Scientific Corporation (BSCI) and assessed both in vitro and
in vivo for its ability to inhibit bacterial survival, biofilm
formation and infection development associated with the
device. Firstly, Chew et al. [32] demonstrated significant
antimicrobial effects in vitro for both the device and its
eluate against numerous uropathogens including Klebsiella
pneumoniae, E. coli, Proteus mirabilis and S. aureus. E.
faecalis and P. aeruginosa were already known to display
partial and complete resistance to triclosan, respectively,
and the same result was found in the study. This work was
followed by an in vivo rabbit study where triclosan-eluting
stent curls were able to clear instilled P. mirabilis in-
fections in over half of the animals tested within 7 days
compared to none of the controls [33]. Following these
initial successes, additional in vitro studies showed that
triclosan could reduce pro-inflammatory cytokine expres-
sion triggered by bacterial challenge or mechanical
disruption using bladder and kidney cell models, and
showed that triclosan worked synergistically with
numerous clinically-relevant antibiotics [34e36]. However,
two clinical trials that were conducted involving both
acute and chronically-stented patients were unable to
demonstrate significant clinical benefits to the device over
controls [37,38]. In the chronic study, subjects harbored a
control stent for 3 months followed by the triclosan-eluting
device. The triclosan group showed no improvement in
device colonization or urine culturing despite a significant
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acute study was a prospective randomized trial investi-
gating the capacity of triclosan stents to reduce stent-
associated infections and biofilm formation in patients
stented for 1e2 weeks. Although no significant differences
in bacteriological parameters were observed between the
groups, the triclosan group showed significant reductions
in several common ureteral-stent-related symptoms.
Overall, it presently remains unclear as to whether tri-
closan has any role in urology in preventing biofilm for-
mation and stent-related infections. However, the anti-
inflammatory effects observed both in vitro and in vivo
alongside its demonstrated synergism with other antimi-
crobials suggest that it could be combined with other
coating strategies to create a stent that would potentially
reduce infection and ease patient discomfort caused by
the device.
3.2. Alternative antimicrobials
Researchers at the M.D. Anderson Cancer Center developed
a technique of loading a urinary catheter with Gendine, a
novel antiseptic dye consisting of Gentian violet and
chlorhexidine [39]. Gendine-coated silicone urinary cathe-
ters were then found to have significantly less adhesion and
colonization by various Gram-positive and negative bacte-
ria compared to the uncoated catheter in vitro. Further,
in vivo studies demonstrated the Gendine-coated catheters
were more effective at preventing device-associated
infection. More recently, Cirioni et al. [40] explored the
interaction of systemic amikacin with a clarithromycin-
eluting stent. Results indicated that this combination
worked synergistically in vivo to prevent device-associated
biofilm formation by P. aeruginosa. A further line of
research involves the combination of protamine sulphate
(PS), an antimicrobial peptide, and chlorhexidine (CHX) in a
catheter coating [41]. Early work by researchers demon-
strated synergy between PS and CHX, particularly against E.
coli. Moreover, CHX and PS coated devices provided
decreased colonization in vitro and increased durability
against both Gram-negative and positive pathogens.
In vivo, the coated devices were found to have reduced E.
coli colonization and device-associated infection. Given the
success of these coatings on catheters (Gendine and CHX
and PS) and combination therapies further in vivo studies
are required to validate their efficacy and safety.
3.3. Ketorolac
Ketorolac is a NSAID that is widely used for postoperative
pain in many surgical areas. Beiko et al. [42] first explored
the use of ketorolac as a local therapy agent within the
urinary tract in 2004. This double-blind randomized trial
assessed the safety and efficacy of intravesical instillation
of numerous agents in reducing ureteral stent-associated
discomfort in patients requiring a stent following extra-
corporeal shockwave lithotripsy. Of the three agents
assessed (ketorolac, oxybutynin, and alkalinized lidocaine)
ketorolac was found to be the most effective agent in
reducing stent-associated discomfort. However, the
reduction in patient discomfort was only notable within thefirst hour, and there was no significant difference in pain
between the ketorolac treatment and control group at
further time points. In 2010, Chew et al. [43] evaluated the
safety of ketorolac-eluting stents in a porcine model. In this
study control, 15%, 13%, or 7% ketorolac-loaded stents were
placed transurethrally and ketorolac levels were measured
in various tissues. Results indicated the ketorolac-eluting
stent was safe as no adverse events, gastric ulcerations or
internal organ abnormalities were noted in any of the
ketorolac-stent groups. Additionally the majority of ketor-
olac was released within the first 30 days. The efficacy of
the ketorolac-eluting stent was then assessed in a pro-
spective, multicenter, randomized, double-blind clinical
trial. At completion the study enrolled 276 participants
across 14 centers throughout the United States [44]. The
study was able to corroborate the safety results of the
aforementioned study, while noting a 49% increase in pa-
tients lowering or eliminating their pain medication in the
ketorolac-eluting stent cohort. Conversely, the ketorolac-
eluting stent did not demonstrate a clear advantage in
reduction of the number of unscheduled physician con-
tacts, early stent removal, pain medication change or pa-
tient assessed pain; however, trends were notable in subset
analyses. Most notably, men and patients under the age of
45 required less pain medication in the treatment group.
Given that other research teams have documented age as a
factor in ureteral stent pain [45], mainly that younger pa-
tients experience more pain, a decrease in pain within this
age group may be critical. While the study incorporated the
use of a validated visual analog pain scoring system it did
not include the use of the ureteric stent symptom ques-
tionnaire (USSQ), the only validated condition specific
questionnaire [46]. The authors accounted for this lack as
the USSQ is designed to assess patient outcome at 1 month;
patients within this trial were stented for 4e10 days,
making the USSQ not practical. However, as pain is a sub-
jective quality, no conclusions can be accurately drawn
from this study without further assessment on the
ketorolac-eluting stents effect on quality of life.
3.4. Paclitaxel
Bare metal stents and metal drug-eluting stents have been
used extensively in the treatment of cardiovascular disease
with much success; recently they have also been applied to
many urological conditions. An example of this is the work
by Liatsikos and colleagues [47] that assessed the use of
paclitaxel-eluting metal mesh stents within the pig ureter.
Paclitaxel is an anticancer agent that promotes polymeri-
zation of tubulin while inhibiting the disassembly of mi-
crotubules; therefore disrupting the normal microtubule
dynamics and causing cell death. Paclitaxel research also
indicates the agent induces the expression of tumor ne-
crosis factor-a (TNF-a) and has an anti-proliferative effect
on bladder urothelium [48,49]. Earlier work also explored
the use of a paclitaxel-eluting polyurethane covered stent
in a canine urethral model; wherein the treatment stent
was found to reduce stent related tissue hyperplasia [50].
This early data made paclitaxel an excellent candidate for
incorporation into the drug-eluting ureteral stent explored
by Liatsikos et al. [47]. The purpose of this study was to
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associated luminal occlusion within the ureter. Re-
searchers found the paclitaxel-eluting stent caused mini-
mal urothelial hyperplasia and limited intraluminal tissue
growth; furthermore there was less inflammation of sur-
rounding tissues. Given the extensive use of paclitaxel-
eluting stents in the treatment of cardiovascular disease
and the early results indicated here it is recommended that
further trials be conducted to better assess the efficacy of
paclitaxel-eluting ureteral stents.
3.5. Zotarolimus and indomethacin
One of the most common adverse effects of a ureteral
metal stent is hyperplastic reaction, thus Kallidonis and
colleagues [51] sought to decrease these effects through
the use of a zotarolimus-eluting stent. Zotarolimus is an
anti-proliferative agent used extensively in cardiological
stents. Researchers evaluated the effect of the
zotarolimus-eluting ureteral stent using both porcine and
rabbit animal models. In the porcine control group 7/10
ureters were completely obstructed, while no obstruction
(0/10) was noted in the porcine treatment group.
Furthermore, 2/6 rabbit control group ureters were
occluded, while none of the treatment group ureters (0/6)
were. Overall, while there was documented hyperplasia in
all groups, lower amounts were associated with the
zotarolimus-eluting stent.
Finally, indomethacin represents another potential
candidate for use in drug-eluting ureteral stents. Early
research into indomethacin, an NSAID, has demonstrated
that it is possible to sustain its elution and that it exhibits
strong biocompatibility [52]. Further, indomethacin-
eluting stent material has been shown to reduce both
monocyte chemotactic protein-1 (MCP-1) and RANTES
(regulated upon activation, normal T-cell expressed, and
secreted), chemokines that regulate the recruitment of
inflammatory cells to tissues during the inflammatory
process [53]. Recent research from Kotsar and colleagues
[54] assessed the effects of an indomethacin-eluting ure-
thral stent in rabbits. Results from the study indicated
that indomethacin is highly biocompatible in an animal
model; however this represents some of the first work
assessing indomethacin as a stent-eluting agent and
further work is required to fine-tune its elution profile and
agent dosage. Regardless, indomethacin and zotarolimus
are both promising agents for potential use in ureteral
drug-eluting stents; further research is required for both
to ensure efficacy and safety.
4. Anti-encrustation coating
While this urinary device review has focused mostly on
infection, inflammation and pain prevention, encrustation
remains a major limiting factor of device usage and effi-
cacy. Recently, Ron and colleagues [55] assessed the in-
fluence of rhenium-doped fullerene-like molybdenum
disulfide (Re:IF-MoS2) nanoparticles as a coating on the
growth and attachment of in vitro encrustation stones on
silicone catheters. Interestingly, the Re:IF-MoS2-coating
displayed a unique tendency to self-assemble into mosaic-like arrangements, modifying the surface in such a way as
to be encrustation-repellent. While the application of
nanoparticle-based coatings in biology is still relatively in
its infancy, they clearly represent a valid method for
achieving desired structures homogeneously over a surface.
This is critically important as surface imperfections are
major sites where bacteria, biological molecules and crys-
tals can attach.
5. Conclusion
Although the perfect ureteral stent does not exist, the
devices continue to improve. Currently, technological in-
novations are focusing on the enhancement and evolution
of stent design, material composition, elutable substances
and surface coatings. Since the two largest hurdles to
overcoming stent related infection and encrustation are
the continuous deposition of host conditioning film material
on the device and the potential for consistent transient
entry of microorganisms into the tract, it is paramount that
novel strategies work in a multi-faceted manner; that is,
targeting both anti-fouling and antimicrobial properties
simultaneously. Indeed, many strategies described herein
were expected to yield more efficacious results based upon
their success in other areas and fields, yet failed when
challenged in an infectious urinary setting. Ultimately,
success may lie in the development of multiple devices,
each with its own clinical target, or in one device that is
able to simultaneously incorporate multiple strategies that
can work in synergy.Conflicts of interest
The authors declare no conflict of interest.References
[1] Cauda F, Cauda V, Fiori C, Onida B, Garrone E. Heparin coating
on ureteral double J stents prevents encrustations: an in vivo
case study. J Endourol 2008;22:465e72.
[2] Lange D, Elwood CN, Choi K, Hendlin K, Monga M, Chew BH.
Uropathogen interaction with the surface of urological stents
using different surface properties. J Urol 2009;182:1194e200.
[3] Laube N. Diamonds are a urologist’s best friend. Available
from: http://www.eurekalert.org/pub_releases/2004-11/
uob-daa111804.php.
[4] Laube N, Bradenahl J, Meissner AV, Rappard J, Kleinen L,
Mu¨ller SC. Plasma-deposited carbon coating on urological
indwelling catheters: preventing formation of encrustations
and consecutive complications. Urol A 2006;45:1163e4. 1166-
9. [Article in German].
[5] Laube N, Kleinen L, Bradenhal J, Meissner A. Diamond-like
carbon coatings on ureteral stents: a new strategy for
decreasing the formation of crystalline bacterial biofilms? J
Urol 2007;177:1923e7.
[6] Lopez-Lopez G, Pascual A, Perea EJ. Effect of plastic catheter
material on bacterial adherence and viability. J Med Microbiol
1991;34:349e53.
[7] Elayarajah B, Rajendran R, Venkatrajah B, Sreekumar Sweda,
Asasudhakar, Janiga PK. Prevention of biofilm formation on
norfloxacinmetronidazole treated ureteral latex stents. Int J
Eng Sci Technol 2011;3:544e51.
200 L. Yang et al.[8] Chung HH, Lee SH, Cho SB, Park HS, Kim YS, Kang B, et al.
Comparison of a new polytetrafluoroethylene-covered
metallic stent to a noncovered stent in canine ureters. Car-
diovasc Interv Radiol 2008;31:619e28.
[9] Morra M. On the molecular basis of fouling resistance. J Bio-
mater Sci Polym Ed 2000;11:547e69.
[10] Dalsin JL, Lin L, Tosatti S, Voros J, Textor M, Messersmith PB.
Protein resistance of titanium oxide surfaces modified by
biologically inspired mPEG-DOPA. Langmuir 2005;21:640e6.
[11] Waite JH, Tanzer ML. The bioadhesive Mytilus byssus: a pro-
tein containing L-dopa. Biochem Biophys Res Commun 1980;
96:1554e61.
[12] Ko R, Cadieux PA, Dalsin JL, Lee BP, Elwood CN, Razvi H. First
prize: novel uropathogenresistant coatings inspired by marine
mussels. J Endourol 2008;22:1153e60.
[13] Pechey A, Elwood CN, Wignall GR, Dalsin JL, Lee BP,
Vanjecek M, et al. Anti-adhesive coating and clearance of
device associated uropathogenic Escherichia coli cystitis. J
Urol 2009;182:1628e36.
[14] Liu XS, Zola JC, McGinnis DE, Squadrito JF, Zeltser IS. Do silver
alloy-coated catheters increase risk of urethral strictures
after robotic-assisted laparoscopic radical prostatectomy?
Urology 2011;78:365e7.
[15] John T, Rajpurkar A, Smith G, Fairfax M, Triest J. Antibiotic
pretreatment of hydrogel ureteral stent. J Endourol 2007;21:
1211e6.
[16] Slawson RM, Van Dyke MI, Lee H, Trevors JT. Germanium and
silver resistance, accumulation, and toxicity in microorgan-
isms. Plasmid 1992;27:72e9.
[17] Davenport K, Keeley FX. Evidence for the use of silver-alloy-
coated urethral catheters. J Hosp Infect 2005;60:298e303.
[18] Beattie M, Taylor J. Silver alloy vs. uncoated urinary cathe-
ters: a systematic review of the literature. J Clin Nurs 2011;
20:2098e108.
[19] Lopez-Leban F, Kiran MD, Wolcott R, Balaban N. Molecular
mechanisms of RIP, an effective inhibitor of chronic in-
fections. Int J Artif Organs 2010;33:582e9.
[20] Cirioni O, Giacometti A, Kamysz W, Silvestri C, Riva A, Della
Vittoria A, et al. In vitro activities of the antimicrobial pep-
tide tachyplesin III against Pseudomonas aeruginosa. Peptides
2007;28:747e51.
[21] Balaban N, Stoodley P, Fux CA, Wilson S, Costerton JW,
Dell’Acqua G. Prevention of staphylococcal biofilm-associated
infections by the quorum sensing inhibitor RIP. Orthop Relat
Res 2005;437:48e54.
[22] Kiran MD, Adikesavan NV, Cirioni O, Giacometti A, Silvestri C,
Scalise G, et al. Discovery of a quorum-sensing inhibitor of
drug-resistant staphylococci infections by structure-based
virtual screening. Mol Pharmacol 2008;73:1578e86.
[23] Muta T, Fujimoto T, Nakajima H, Iwanaga S. Tachyplesins
isolated from hemocyte of Southeast Asian horseshoe crabs
(Carcinoscorpius rotundicauda and Tachypleus gigas): identi-
fication of a new tachyplesin, tachyplesin III, and a processing
intermediate of its precursor. J Biochem 1990;108:261e6.
[24] Minardi D, Ghiselli R, Cirioni O, Giacometti A, Kamysz W,
Oriando F, et al. The antimicrobial peptide tachyplesin III
coated alone and in combination with intraperitoneal
piperacillin-tazobactam prevents ureteral stent Pseudomonas
infection in a rat subcutaneous pouch model. Peptides 2007;
28:2293e8.
[25] Wilcox MDP, Hume EBH, Aliwarga Y, Kumar N, Cole N. A novel
cationic-peptide coating for the prevention of microbial
colonization on contact lenses. J Appl Microbiol 2008;105:
1817e25.
[26] Cole N, Hume EBH, Vijay AK, Sankaridurg P, Kumar N,
Wilcox MDP. In vivo performance of melimine as an antimi-
crobial coating for contact lenses in models of CLARE and
CLPU. Investigative Ophthalmol Vis Sci 2010;51:390e5.[27] Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ,
Pietrow PK, et al. A prospective, randomize, double-blinded
placebo-controlled comparison of extended release oxy-
butynin versus phenazopyridine for the management of post-
operative ureteral stent discomfort. J Urol 2008;71:792e5.
[28] Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K,
Monga M. Alfuzosin to relieve ureteral stent discomfort: a
prospective, randomized, placebo controlled study. J Urol
2009;181:170e6.
[29] Bhargava HN, Leonard PA. Triclosan: applications and safety.
Am J Infect Control 1996;24:209e18.
[30] Heath RJ, White SW, Rock CO. Inhibitors of fatty acid synthesis
as antimicrobial chemotherapeutics. Appl Microbiol Bio-
technol 2002;58:695e703.
[31] Heath RJ, Yu YT, Shapiro MA, Olson E, Rock CO. Broad spec-
trum antimicrobial biocides target the FabI component of
fatty acid synthesis. J Biol Chem 1998;273:30316e20.
[32] Chew BH, Cadieux PA, Reid G, Denstedt JD. In-vitro activity of
triclosaneluting ureteral stents against common bacterial
uropathogens. J Endourol 2006;20:949e58.
[33] Cadieux PA, Chew BH, Knudsen BE, Dejong K, Rowe E, Reid G,
et al. Triclosan loaded ureteral stents decrease proteus mir-
abilis 296 infection in a rabbit urinary tract infection model. J
Urol 2006;175:2331e5.
[34] Wignall GR, Goneau LW, Chew BH, Denstedt JD, Cadieux PA.
The effects of triclosan on uropathogen susceptibility to
clinically relevant antibiotics. J Endourol 2008;22:2349e56.
[35] Elwood CN, Chew BH, Seney S, Jass J, Denstedt JD,
Cadieux PA. Triclosan inhibits uropathogenic Escherichia coli-
stimulated tumor necrosis factor-alpha secretion in T24
bladder cells in vitro. J Endourol 2007;21:1217e22.
[36] Elwood CN, Lange D, Nadeau R, Seney S, Summers K,
Chew BH, et al. Novel in vitro model for studying ureteric
stent-induced cell injury. BJU Int 2010;105:1318e23.
[37] Cadieux PA, Chew BH, Nott L, Elwood CN, Wignall GR,
Goneau LW, et al. The use of triclosan-eluting ureteral
stents in long-term stented patients. J Endourol 2009;23:
1187e94.
[38] Mendez-Probst CE, Goneau LW, Macdonald KW, Nott L, Seny S,
Elwood CN, et al. The use of triclosan eluting stents effec-
tively reduces ureteral stent symptoms: a prospective ran-
domized trial. BJU Int 2012;110:749e54.
[39] Hachem R, Reitzel R, Borne A, Jiang Y, Tinkey P,
Uthamanthil R, et al. Novel antiseptic urinary catheters for
prevention of urinary tract infections: correlation of in vivo
and in vitro test results. Antimicrob Agents Chemother 2009:
5145e9.
[40] Cirioni O, Ghiselli R, Silvestri C, Minardi D, Gabrielli E,
Orlando F, et al. Effect of the combination of clarithromycin
and amikacin on Pseudomonas aeruginosa biofilm in an animal
model of ureteral stent infection. J Antimicrob Chemother
2011;66:1318e23.
[41] Darouiche RO, Mansouri MD, Gawande PV, Madhyastha S. Ef-
ficacy of combination of chlorhexidine and protamine sul-
phate against device-associated pathogens. J Antimicrob
Chemother 2008;61:651e7.
[42] Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE,
Brock GB, et al. Double-blind randomized controlled trial
assessing the safety and efficacy of intravesical agents for
ureteral stent symptoms after extracorporeal shockwave
lithotripsy. J Endourol 2004;18:723e30.
[43] Chew B, Davoudi H, Li J, Denstedt JD. An in vivo porcine
evaluation of the safety, bioavailability and tissue penetration
of ketorolac drug eluting ureteral stent designed to improve
comfort. J Endourol 2010;24:1023e9.
[44] Krambeck AE, Walsh RS, Denstedt JD, Preminger GM, Li J,
Evans JC, et al. A novel drug eluting ureteral stent: a pro-
spective, randomized, multicenter clinical trial to evaluate
Drug-eluting stents and stent coatings 201the safety and effectiveness of a ketorolac loaded ureteral
stent. J Urol 2010;183:1037e42.
[45] Irani J, Siquier J, Pire`s C, Lefebvre O, Dore´ B, Aubert J.
Symptom characteristics and the development of tolerance
with time in patients with indwelling double-pigtail ureteric
stents. BJU Int 1999 Aug;84:276e9.
[46] Dellis A, Joshi HB, Timoney AG, Keeley FX. Relief of stent
related symptoms: review of engineering and pharmacological
solutions. J Urol 2010;184:1267e72.
[47] Liatsikos EN, Karnabatidis D, Kagadis GC, Rokkas K,
Constantinides C, Christeas N, et al. Application of paclitaxel-
eluting metal mesh stents within the pig ureter: an experi-
mental study. Eur Urol 2007;51:217e23.
[48] Purohit A, Singh A, Ghilchik MW, Reed MJ. Inhibition of tumor
necrosis factor alpha-stimulated aromatase activity by
microtubule-stabilizing agents, paclitaxel and 2-methox-
yestradiol. Biochem Biophysical Res Commun 1999;261:
214e7.
[49] Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics
of intravesical taxol. Cancer Chemother Pharmacol 1997;40:
285e92.[50] Shin JH, Song HY, Choi CG, Yuk SH, Kim JS, Kim YM, et al.
Tissue hyperplasia: influence of a paclitaxel-eluting covered
stent e preliminary study in a canine urethral model. Radi-
ology 2005;234:438e44.
[51] Kallidonis P, Kitrou P, Karnabatidis D, Kyriazis I,
Kalogeropoulou C, Tsamandas A, et al. Evaluation of
zotarolimus-eluting metal stent in animal ureters. J Endourol
2011;25:1661e7.
[52] Uurto I, Kotsar A, Isotalo T, Martilkainen PM, Kellomaki M,
Tormala P, et al. Tissue biocompatibility of new biodegradable
drug-eluting stent materials. J Mater Sci Mater Med 2007;18:
1543e7.
[53] Andrich DE, Mundy AR. What is the best technique for ure-
throplasty? Eur Urol 2008;54:1031e41.
[54] Kotsar A, Nieminen R, Isotalo T, Mikkonen J, Uurto I,
Kellomaki M, et al. Preclinical evaluation of new
indomethacin-eluting biodegradable urethral stent. J
Endourol 2012;26:387e92.
[55] Ron R, Zbaida D, Kafka IZ, Rosentsveig R, Leibovitch I,
Tenne R. Attenuation of encrustation by self-assembled inor-
ganic fullerene-like nanoparticles. Nanoscale 2014;6:5251e9.
